{"id":7473,"date":"2024-07-04T14:24:53","date_gmt":"2024-07-04T14:24:53","guid":{"rendered":"https:\/\/neuropediatoolkit.org\/?p=7473"},"modified":"2026-11-01T07:32:23","modified_gmt":"2026-11-01T07:32:23","slug":"medicina-de-precision-en-epilepsia-genetica","status":"publish","type":"post","link":"https:\/\/neuropediatoolkit.org\/en\/medicina-de-precision-en-epilepsia-genetica\/","title":{"rendered":"Precision medicine in genetic epilepsy."},"content":{"rendered":"<h2 class=\"wp-block-heading\">Precision Medicine in Genetic Epilepsy<\/h2>\n\n\n<p class=\"wp-block-paragraph\">Precision medicine in genetic epilepsy identifies the underlying molecular cause to guide specific treatments, avoiding ineffective or harmful therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter\">\n  <img fetchpriority=\"high\" decoding=\"async\" width=\"850\" height=\"541\" src=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2024\/07\/Epilepsy-related-genetic-conditions-displaying-potential-specific-therapeutic-approaches.png\" alt=\"Epilepsy-related genetic conditions displaying potential specific therapeutic approaches\" class=\"wp-image-7474\" srcset=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2024\/07\/Epilepsy-related-genetic-conditions-displaying-potential-specific-therapeutic-approaches.png 850w, https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2024\/07\/Epilepsy-related-genetic-conditions-displaying-potential-specific-therapeutic-approaches-300x191.png 300w, https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2024\/07\/Epilepsy-related-genetic-conditions-displaying-potential-specific-therapeutic-approaches-768x489.png 768w, https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2024\/07\/Epilepsy-related-genetic-conditions-displaying-potential-specific-therapeutic-approaches-18x12.png 18w\" sizes=\"(max-width: 850px) 100vw, 850px\" \/>\n  <figcaption>Figure: Genetic conditions associated with epilepsy and their targeted therapies. Shows molecular targets and specific treatments according to the affected gene.<\/figcaption>\n<\/figure>\n\n\n<h3 class=\"wp-block-heading\">Therapeutic Approaches by Genetic Group<\/h3>\n\n\n<ul class=\"wp-block-list\">\n  <li><strong>Channelopathies (SCN1A, KCNQ2, etc.)<\/strong>\n    <ul>\n      <li>Avoid <em>carbamazepine<\/em> y <em>phenytoin<\/em> in <em>SCN1A<\/em> loss of function (risk of worsening seizures).<\/li>\n      <li>Treatments of choice: <em>fenfluramina<\/em>, <em>cannabidiol<\/em>, <em>stiripentol<\/em>, <em>clobazam<\/em>, <em>valproate<\/em>.<\/li>\n    <\/ul>\n  <\/li>\n  <li><strong>Metabolic disorders<\/strong>\n    <ul>\n      <li><em>SLC2A1<\/em>: ketogenic diet (replaces glucose with ketone bodies).<\/li>\n      <li><em>ALDH7A1<\/em> y <em>PNPO<\/em>: supplementation with <em>pyridoxine<\/em> o <em>PLP<\/em>.<\/li>\n    <\/ul>\n  <\/li>\n  <li><strong>mTORopathies (TSC1\/TSC2, DEPDC5)<\/strong>\n    <ul>\n      <li>Treatment: <em>everolimus<\/em> y <em>sirolimus<\/em> (mTOR inhibitors).<\/li>\n      <li>Effective in refractory epilepsy and focal cortical dysplasias.<\/li>\n    <\/ul>\n  <\/li>\n  <li><strong>Synaptic alterations (GRIN2A\/B, PCDH19)<\/strong>\n    <ul>\n      <li><em>Memantine<\/em>: for gain of function in <em>GRIN2A\/B<\/em>.<\/li>\n      <li><em>Ganaxolone<\/em> and hormonal therapies: in <em>PCDH19<\/em>.<\/li>\n    <\/ul>\n  <\/li>\n<\/ul>\n\n\n\n<div id=\"wp-block-themeisle-blocks-accordion-9aaa717b\" class=\"wp-block-themeisle-blocks-accordion exclusive\">\n<details class=\"wp-block-themeisle-blocks-accordion-item\"><summary class=\"wp-block-themeisle-blocks-accordion-item__title\"><div>Key Source Details<\/div><\/summary><div class=\"wp-block-themeisle-blocks-accordion-item__content\"><p class=\"wp-block-paragraph\">\u2022 Beltr\u00e1n-Corbellini et al. (2022): Genetic identification allows reduction of iatrogenesis, better prognosis and personalized therapeutic planning.<\/p>\n\n<p class=\"wp-block-paragraph\">\u2022 Moloney et al. (2022): Genetics should be integrated into presurgical evaluation. In <em>SCN1A<\/em>, surgery has worse outcomes, but should not be excluded based on genetics alone.<\/p>\n\n<p class=\"wp-block-paragraph\">\u2022 Myers &amp; Mefford (2015): Genetic epilepsy is highly heterogeneous. New genes have been identified in pathways such as mTOR, chromatin remodeling and transcriptional regulation.<\/p>\n\n<\/details><\/div><\/details>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Genetic identification is key to avoiding ineffective therapies and improving quality of life. Requires multidisciplinary evaluation and clinical surveillance.<\/p>","protected":false},"excerpt":{"rendered":"<p>Precision Medicine in Genetic Epilepsy Precision medicine in genetic epilepsy identifies the underlying molecular cause to guide specific treatments, avoiding ineffective or harmful therapies. Therapeutic Approaches by Genetic Group Channelopathies (SCN1A, KCNQ2, etc.) Avoid carbamazepine and phenytoin in SCN1A loss of function (risk of worsening seizures). Treatments of choice: fenfluramine, cannabidiol, stiripentol,\u2026 <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/neuropediatoolkit.org\/en\/medicina-de-precision-en-epilepsia-genetica\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> \"Precision medicine in genetic epilepsy.\"<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":7474,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-7473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epilepsia","entry"],"_links":{"self":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/comments?post=7473"}],"version-history":[{"count":6,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7473\/revisions"}],"predecessor-version":[{"id":8999,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/posts\/7473\/revisions\/8999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media\/7474"}],"wp:attachment":[{"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/media?parent=7473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/categories?post=7473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/en\/wp-json\/wp\/v2\/tags?post=7473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}